Tinidazole Property

Melting point:

118-120?C

Boiling point:

528.4±30.0 °C(Predicted)

Density 

1.4338 (rough estimate)

refractive index 

1.6320 (estimate)

storage temp. 

Sealed in dry,Room Temperature

solubility 

Practically insoluble in water, soluble in acetone and in methylene chloride, sparingly soluble in methanol.

pka

2.30±0.34(Predicted)

color 

Off-White to Pale Yellow

λmax

317nm(H2O)(lit.)

Merck 

14,9447

BRN 

618182

Stability:

Stable. Incompatible with strong oxidizing agents.

InChIKey

HJLSLZFTEKNLFI-UHFFFAOYSA-N

CAS DataBase Reference

19387-91-8(CAS DataBase Reference)

Safety

Hazard Codes 

Xn

Risk Statements 

20/21/22-40

Safety Statements 

26-36

WGK Germany 

3

RTECS 

NI6255000

HS Code 

2933290000

Hazardous Substances Data

19387-91-8(Hazardous Substances Data)

Toxicity

LD50 in mice (mg/kg): >3600 orally; >2000 i.p. (Miller)

Hazard and Precautionary Statements (GHS)

Symbol(GHS)

Signal word

Warning

Hazard statements

H341Suspected of causing genetic defects

H351Suspected of causing cancer

Precautionary statements

P201Obtain special instructions before use.

P202Do not handle until all safety precautions have been read and understood.

P280Wear protective gloves/protective clothing/eye protection/face protection.

P308+P313IF exposed or concerned: Get medical advice/attention.

Tinidazole Chemical Properties,Usage,Production

Pharmacology and mechanism of action

Similar to metronidazole.

Pharmacology and mechanism of action

Similar to metronidazole.
 

Indications

Infections caused by Entamoeba histolytica and Giardia lamblia. Tinidazole is more effective than metronidazole in the treatment of giardiasis.
 

Side effects

Side effects are similar to but milder than those caused by metronidazole. Gastrointestinal disturbances like nausea, vomiting, anorexia and metallic taste are common. Headache, tiredness, furred tongue and itching may occur. Thrombophlebitis may occur at the site of intravenous infusion ^[1].
 

Contraindications

Tinidazole should not be taken together with alcohol.
 

Interactions

A disulfiram-like reaction might occur if tinidazole is taken together with alcohol.
 

Preparations

• Fasigyn® (Pfizer). Tablets 150 mg, 200 mg, 300 mg, 500 mg, 1 g. Oral suspension 200 mg per ml. Solution for injection 2 mg per ml.
• Tricolam® (Pfizer). Tablets 500 mg.
• Simplotan® (Pfizer). Tablets 1 g.
 

References

1. Sawyer PR, Brogden RN, Pinder RM, Speight TM, Avery GS (1976). Tinidazole: a review of its antiprotozoal activity and therapeutic efficacy. Drugs, 11, 424–440.

Chemical Properties

solid

Originator

Simplotan,Pfizer,W. Germany,1971

Uses

Antiprotozoal (Trichomonas, Giardia); antiamebic; antibacterial.

Uses

anticonvulsant

Uses

anti-ulcerative

Uses

For the treatment of trichomoniasis caused by T. vaginalis in both female and male patients. Also for the treatment of giardiasis caused by G. duodenalis in both adults and pediatric patients older than three years of age and for the treatment of intestin

Definition

ChEBI: Tinidazole is 1H-imidazole substituted at C-1 by a (2-ethylsulfonyl)ethyl group, at C-2 by a methyl group and at C-5 by a nitro group. It is used as an antiprotozoal, antibacterial agent. It has a role as an antiprotozoal drug, an antibacterial drug, an antiparasitic agent and an antiamoebic agent.

Manufacturing Process

The preparation of ethylsulfonylethyl-p-toluenesulfonate is carried out in the following manner: 69.0 grams (0.5 mol) ethylsulfonylethanol dissolved in 150 ml pyridine is cooled to 0°C with stirring and while maintaining the temperature between 0° to 10°C, 95 grams (0.5 mol) p-toluenesulfonyl chloride is added in portions over a 10 minute period. After this time, 250 ml water is added slowly and the mixture extracted with chloroform, the organic phase washed first with 2 N HCl, then with water, separated and dried. The product which crystallizes on cooling is filtered and dried to give 77.5% yield of this intermediate.
A mixture of 12.7 grams (0.1 mol) of 2-methyl-5-nitroimidazole and 58.4 grams (0.2 mol) ethylsulfonylethyl-p-toluenesulfonate is heated with stirring, under nitrogen, at 145° to 150°C for about 4 hours. After this time, the reaction mixture is extracted with 500 ml hot water, the aqueous portion adjusted with 10% Na2CO3 to a pH of 9 and extracted with chloroform (3 times with 150 ml portions). The separated organic phase is washed with water, dried with Na2SO4 and evaporated to dryness. The crude tinidazole product is then crystallized from benzene to give 4.36 grams of product having a MP of 127° to 128°C.

Therapeutic Function

1-[2-(Ethylsulfonyl)ethyl]-2-methyl-5-nitroimidazole

Antimicrobial activity

Its antibacterial and antiprotozoal activity is similar to that of metronidazole.The MIC against G. vaginalis is 0.2–2 mg/L; the hydroxy metabolite is significantly more active than that of metronidazole. H. pylori is inhibited by 0.5 mg/L. T. vaginalis and T. fetus at 2.5 mg/L and E. histolytica is inhibited by about 0.3–2.5 mg/L.

Pharmaceutical Applications

A 5-nitroimidazole available for oral administration and, in some countries, for intravenous infusion.

Mechanism of action

Tinidazole has a mechanism of action that parallels that of metronidazole as well as a similar metabolic pathway leading to hydroxylation at the 2-methyl group catalyzed by CYP3A4. Basically, tinidazole appears to mimic the actions of metronidazole, although there are reports that it is effective against some protozoa which are resistant to metronidazole.

Pharmacokinetics

Oral absorption ：>95%
Cmax 2 g oral：40 mg/L after 2 h
800 mg (30-min infusion)： 12 mg/L 6 min after end infusion
Plasma half-life： 12–14 h
Volume of distribution 0.64 L/kg ：Plasma protein binding 12%
absorption and distribution
After a 2 g oral dose, concentrations remain at c. 10 mg/L at 24 h and 2.5 mg/L at 48 h. Daily doses of 1 g maintain plasma levels in excess of 8 mg/L, irrespective of whether the dose is oral or intravenous. It is well distributed, with concentrations in bile, CSF, breast milk and saliva similar to those reached in plasma.
The drug readily crosses the placenta. In women undergoing first trimester abortion, concentrations of 4.9 mg/kg (placenta) and 7.6 mg/kg (fetus) were found when the plasma concentration was 13.2 mg/L.
Metabolism and excretion
Metabolites include the 2-hydroxymethyl derivative, its glucuronide and two unidentified minor derivatives. In urine about half the drug remains unmetabolized.
The parent drug and its metabolites are excreted primarily in the urine and to a minor extent in the feces. The clearance rate is about 0.73 mL/min per kg and the urinary excretion is about 21% of the dose. Total clearance of the drug is 51 mL/min, renal clearance 10 mL/min. In healthy volunteers given an ： intravenousinfusion of 800 mg [14C]tinidazole over 30 min, a mean of 44% of the dose was excreted in the urine during the first 24 h, increasing to 63% over 5 days： only 12% of the dose appeared in the feces. Unchanged tinidazole comprised 32% of urinary 14C in 0&ndash：12 h urine. The 2-hydroxymethyl metabolite accounted for about 9% of the urinary 14C and was also present in plasma.
In renal failure the pharmacokinetics are not significantly different from those in healthy individuals. It is rapidly removed by hemodialysis and a normal dose should be given after each dialysis： if treatment precedes dialysis a half dose should be infused after the end of the procedure.

Clinical Use

Anaerobic bacterial infections(prophylaxis and treatment)
Trichomoniasis
Giardiasis (single dose) Amebiasis (including amebic liver abscess)
Bacterial vaginosis
Gastric colonization with H. pylori (in combination with other agents)

Side effects

Tinidazole is generally well tolerated. Infrequent and transient effects include nausea, vomiting, diarrhea and a metallic taste. Disulfiram-like reactions may occur and rare neurological disturbances and transient leukopenia have been described. Rash, which may be severe, urticaria and angioneurotic edema can occur.

Synthesis

Tinidazole, 1-2-(ethylsulfonyl)ethyl-2-methyl-5-nitroimidazole (37.2.12), is also made from 2-methyl-5-nitroimidazole (37.2.9), which upon being reacted with 2-ethoxysulfonyl-p-toluenesulfonate (37.2.11) transformed into the desired tinidazole.
The 2-ethoxysulfonyl-p-toluenesulfonate (37.2.11) necessary for this reaction is in turn made by tosylation of 2-ethylsulfonyl ethanol using p-toluenesulfonyl chloride.

Veterinary Drugs and Treatments

Little information is presently available on the use of tinidazole in dogs, cats, or horses. It potentially could be useful for treating anaerobic infections, particularly associated with dental infections in small animals. Because of its antiprotozoal effects, it has been used as an alternative for treating giardiasis in small animals, and it could have efficacy against amebiasis, trichomoniasis or balantidiasis in veterinary species, but documentation of efficacy is not available. Tinidazole has a longer duration of action in dogs and cats than does metronidazole. In humans, oral tinidazole is FDA-approved for treating extraintestinal and intestinal amebiasis, (Entamoeba histolytica), giardiasis (Giardia duodenalis/lamblia), and trichomoniasis (T. vaginalis).

Drug interactions

Potentially hazardous interactions with other drugs
Alcohol: disulfiram-like reaction.

Metabolism

Tinidazole is excreted by the liver (up to 5
%) and kidneys as unchanged drug and metabolites. An active hydroxy metabolite has been identified.